Industry First: For-Profit Donates Rights of Potential New Pediatric Leukemia Drug to Non-Profit

Notable Labs Notable Labs was created after founder, Matt De Silva, felt he was left in a helpless point, following a year of research on treatment options for his father's Glioblastoma…

Continue Reading Industry First: For-Profit Donates Rights of Potential New Pediatric Leukemia Drug to Non-Profit
Results of Levodopa Study Highlight Why Better Parkinson’s Disease Therapies are Needed
sabinevanerp / Pixabay

Results of Levodopa Study Highlight Why Better Parkinson’s Disease Therapies are Needed

According to a story from Parkinson's News Today, a recent study published in the New England Journal of Medicine highlights the key weakness of Levodopa, one of the most common treatments…

Continue Reading Results of Levodopa Study Highlight Why Better Parkinson’s Disease Therapies are Needed
Recently Approved Drug Ultomiris Performs Well in Atypical Hemolytic Uremic Syndrome Trial
qimono / Pixabay

Recently Approved Drug Ultomiris Performs Well in Atypical Hemolytic Uremic Syndrome Trial

According to a story from statnews.com, the biotechnology company Alexion Pharmaceuticals recently announced that its product Ultomiris, which was recently approved as a treatment for paroxysmal nocturnal hemoglobinuria, was also…

Continue Reading Recently Approved Drug Ultomiris Performs Well in Atypical Hemolytic Uremic Syndrome Trial

Phase 2 Trial Results for Epidermolysis Bullosa Coming Second Quarter of 2019

Epidermolysis Bullosa Epidermolysis Bullosa (EB) refers to a group of rare conditions which are characterized by fragile skin. Basically, the disease is caused by separation between the layers of the skin.…

Continue Reading Phase 2 Trial Results for Epidermolysis Bullosa Coming Second Quarter of 2019